Although there is sufficient evidence of associations between increased haematocrit and haemoglobin and SGLT2 inhibitor therapy amongst patients with T2DM, increases in haematocrit have not been consistently observed in several studies.15 This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.